Respironics, Inc. appears in the linked FDA records as the applicant for mask devices reviewed by the Anesthesiology panel. The most recent record is K261262 for the Altis Full Face Mask, received April 16, 2026 and decided September 25, 2026 as substantially equivalent. Earlier records show the same applicant name on mask submissions under product codes BZD and CBK, which places the documented activity in respiratory interface hardware rather than in ventilators or monitoring equipment. The records identify an applicant and its filed devices; they do not establish ownership, a parent company or a brand relationship. [1][3][4]
The Altis Full Face Mask filing
K261262 covers the Altis Full Face Mask under product code BZD, regulation 21 CFR 868.5905, device class 2, with the Anesthesiology review panel. The decision is recorded as substantially equivalent, the submission type as Traditional, and the review as not conducted by a third party. The filing includes a summary rather than only a statement. The applicant address on the record is 1001 Murry Ridge Ln., Murrysville, Pennsylvania, which is a filing address and not evidence of a corporate headquarters. [1][2][4]
The stated indication is to provide an interface for the application of non-invasive positive airway pressure therapy. One indexed description adds that the mask is intended for reuse in home and healthcare or hospital environments and is not intended for critical care patients. These are manufacturer statements reproduced in the filing record; the public documents do not report independent performance testing or comparative results. [3][6]
Earlier mask submissions under the same applicant name
A December 30, 2024 FDA letter addresses Respironics, Inc. at the same Murrysville address regarding K243394, the AF531 Oro-Nasal SE Face Mask. That record lists regulation 21 CFR 868.5895 for continuous ventilators, class II, product code CBK, and describes the device as designed for single-patient use in hospital or institutional settings. The letter references an earlier AF531 SE Full Face Mask clearance, K101129, also under CBK. [5]
A July 28, 2023 letter addresses Respironics Inc. regarding K231313, the Therapy Mask 3100 NC/SP, under regulation 21 CFR 868.5905 and product code BZD. The letter identifies the submission as a CBE Special 510(k) and names the Therapy Mask 3100 NC/SP under K210386 as the predicate device. Read together with K261262, the records show a series of mask clearances spanning 2023 through 2026 under the same applicant name and adjacent regulatory classifications. [7]
What the supplied collection shows
The supplied portfolio snapshot, retrieved November 20, 2026, links one record for this company, a 510(k) with a substantially equivalent decision. The record sample contains that single entry, K261262, and the sample decision counts match the full collection at one. These figures describe the supplied filings as of that retrieval date; they are not measures of total company sales, total product portfolio, market position or safety performance. [1]
The indexed record for K261262 also lists related product-code and regulation entries and neighboring mask clearances from other applicants, including full face masks decided in 2025. Those neighboring rows belong to other companies and are not Respironics filings. The public documents do not document recalls, post-market actions or commercial availability for the Altis mask, and no such claims are made here. [4]
